FDA Approves Skytrofa

FDA Approves Skytrofa (lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Pediatric Growth Hormone Deficiency COPENHAGEN, Denmark, Aug. 25, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to potentially create new treatments that make a meaningful difference in patients’ lives, today announced that the U.S. Food and Drug Administration (FDA) has approved […]

Continue reading »

FDA Approves Expanded Botox (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity

NORTH CHICAGO, Ill., July 29, 2021 /PRNewswire/ — Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of Botox® to include eight new muscles for the treatment of upper limb spasticity in adults. The new muscles for treatment include additional muscles of the elbow and forearm (brachialis, brachioradialis, […]

Continue reading »

Journalists Track Biden’s First 100 Days

Chief Washington correspondent Julie Rovner discussed Biden’s first 100 days on WAMU/NPR’s “1A” on Wednesday. She also joined Wisconsin Public Radio’s “Central Time” to talk about why hospitals aren’t cooperating with price transparency requirements. Click here to hear Rovner on WAMU/NPR Read Rovner’s “The Great Undoing: Which of Trump’s Policies Will Biden Reverse?” Click here to hear Rovner on Wisconsin […]

Continue reading »

Scientists Seek Covid Treatment Answers in Cheap, Older Drugs

Could a decades-old antidepressant be a secret weapon against covid? A few scientists think so, after two small studies showed that fluvoxamine, typically prescribed for obsessive-compulsive disorder, prevented serious illness in all participants who took the pills soon after developing symptoms. It’s an exciting notion: A $10, two-week course of this drug could reduce death and hospitalizations. The drug could […]

Continue reading »

FDA Approves Ponvory

FDA Approves Ponvory (ponesimod) for the Treatment of Adults with Relapsing Multiple Sclerosis TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved Ponvory™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), […]

Continue reading »

Micardis® (Telmisartan) Consumer Medicine Information

  Micardis® Tablets Telmisartan Consumer Medicine Information     NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. This page contains answers to some common questions about Micardis®. It does not contain all the information that is known about Micardis®. It does not take the place of talking to your doctor or pharmacist. All medicines have […]

Continue reading »

APOTEX-Pioglitazone

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. APOTEX-PIOGLITAZONE Pioglitazone hydrochloride Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about pioglitazone. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your […]

Continue reading »

Noralin

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. NORALIN Solution for intravenous infusion 3 mg/50 mL, 5 mg/50 mL, 6 mg/50 mL & 10 mg/50 mL Noradrenaline (norepinephrine) (as acid tartrate monohydrate) Consumer Medicine Information What is in this leaflet Please read this leaflet carefully before you are given Noralin. This leaflet answers some common […]

Continue reading »

Olmesartan/Amlodipine APOTEX

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. OLMESARTAN/AMLODIPINE APOTEX Olmesartan medoxomil and amlodipine besilate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about this medicine. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines […]

Continue reading »
1 2 3 13